Results 21 to 30 of about 1,717 (156)

Synovial fluid and plasma concentrations of tedizolid in patients with osteoarthritis infected with Staphylococcus aureus effectively determined with fluorescence detection

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Tedizolid is a new oxazolidinone antibiotic with high potency for the treatment of infections caused by methicillin-resistant Staphylococcus aureus and other species.
Daisuke Negishi, Okimichi Mitsumatsu, Hiromi Mitsumatsu, Miaki Makiguchi, Makiko Shimizu, Hiroshi Yamazaki   +5 more
doaj   +1 more source

Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs

Antibiotics, 2021
Background: To evaluate the efficacy and safety of long-term use of tedizolid in osteoarticular infections. Methods: Multicentric retrospective study (January 2017–March 2019) of osteoarticular infection cases treated with tedizolid.
Eva Benavent, Laura Morata, Francesc Escrihuela-Vidal, Esteban Alberto Reynaga, Laura Soldevila, Laia Albiach, Maria Luisa Pedro-Botet, Ariadna Padullés, Alex Soriano, Oscar Murillo   +9 more
doaj   +1 more source

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections

Antibiotics, 2023
Skin and soft tissue infections (SSTIs) are associated with significant morbidity and healthcare costs, especially when caused by methicillin-resistant Staphylococcus aureus (MRSA).
Sofia Maraki, Viktoria Eirini Mavromanolaki, Dimitra Stafylaki, Evangelia Iliaki-Giannakoudaki, George Hamilos   +4 more
doaj   +1 more source

Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis

Antibiotics, 2019
This meta-analysis aims to assess the efficacy and safety of tedizolid, compared to linezolid, in the treatment of acute bacterial skin and skin structure infection (ABSSSI). PubMed, Web of Science, EBSCO (Elton B.
Shao-Huan Lan, Wei-Ting Lin, Shen-Peng Chang, Li-Chin Lu, Chien-Ming Chao, Chih-Cheng Lai, Jui-Hsiang Wang   +6 more
doaj   +1 more source

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis

Frontiers in Pharmacology, 2021
Background:Mycobacteriumtuberculosis [Mtb] could be present in different metabolic population in the lung lesions, and nonreplicating persisters [NRP], associated with latent tuberculosis [TB], are the most difficult to kill.Objective: Test the ...
Shashikant Srivastava, Shashikant Srivastava, Shashikant Srivastava, Kayle N. Cirrincione, Devyani Deshpande, Tawanda Gumbo, Tawanda Gumbo, Tawanda Gumbo   +7 more
doaj   +1 more source

Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting

Infectious Diseases and Therapy, 2020
Introduction Outcomes data for patients who received tedizolid for acute bacterial skin and skin-structure infections (ABSSSIs) are scant. We provide a real-world analysis of economic and clinical outcomes following tedizolid use in the outpatient ...
Ravina Kullar, Laura A. Puzniak, Jason P. Swindle, Thomas Lodise   +3 more
doaj   +1 more source

In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

International Journal of Infectious Diseases, 2019
Objective: We tested the in vitro susceptibility to Tedizolid and Dalbavancin of Methicillin-resistant Staphylococcus aureus strains recovered from blood and wound cultures, and compared our results with studies conducted in the last four years.
Maya Azrad, Motti Baum, Assaf Rokney, Yish Levi, Avi Peretz   +4 more
doaj   +1 more source

Actividad in vitro del tedizolid y de antibióticos de comparación en aislamientos de Staphylococcus aureus resistentes a meticilina en infecciones de piel y tejidos blandos en siete hospitales de Colombia

Biomédica: revista del Instituto Nacional de Salud, 2018
Introducción. Staphylococcus aureus resistente a meticilina (SARM) causa infecciones graves de la piel y los tejidos blandos en los hospitales y, en los últimos años, en la comunidad.
Aura Lucía Leal, María Victoria Ovalle, Jorge Alberto Cortés, Anita María Montañes, Zandra Rocío de la Rosa, José Yesid Rodríguez, Sandra Gualtero, Beatriz Ariza, Otto Sussman, María del Pilar Torres   +9 more
doaj   +1 more source

In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid

Brazilian Journal of Infectious Diseases, 2017
Introduction: Treatment of multidrug-resistant Gram-positive infections caused by Staphylococcus aureus remains as a clinical challenge due to emergence of new resistance mechanisms.
Johanna Marcela Vanegas Múnera, Ana María Ocampo Ríos, Daniela Montoya Urrego, Judy Natalia Jiménez Quiceno   +3 more
doaj   +1 more source

Tedizolid Population Pharmacokinetics, Exposure Response, and Target Attainment [PDF]

Antimicrobial Agents and Chemotherapy, 2014
ABSTRACT Tedizolid phosphate is a novel antibacterial prodrug that is rapidly and extensively converted to its active moiety, tedizolid. We developed a population pharmacokinetics (PK) model for tedizolid using pooled data from seven densely and sparsely sampled clinical trials evaluating oral and intravenous tedizolid.
S, Flanagan, J, Passarell, Q, Lu, J, Fiedler-Kelly, E, Ludwig, P, Prokocimer   +5 more
openaire   +2 more sources